Drugs / quaratusugene ozeplasmid
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05062980 | Mar 2022 → Feb 2025 | non-small cell lung carcinoma | Genprex, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05703971 | May 2024 → Dec 2027 expected | small cell lung carcinoma | Genprex, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04486833 | Sep 2021 → Mar 2028 expected | non-small cell lung carcinoma | Genprex, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 20
| Date | Issuer | Release |
|---|---|---|
| 2026-05-26 | Genprex, Inc. | Results Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting genprex.com ↗
In patients with NSCLC, Trop-2 H-scores above 100 correlated with prolonged PFS (p=0.05), and PTEN H-scores below 100 correlated with prolonged PFS (p=0.03). |
| 2026-04-20 | Genprex, Inc. | Results Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting genprex.com ↗
The collaborators presented positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid, also referred to as Quar Oze), for the treatment of lung cancer. |
| 2026-03-18 | Genprex, Inc. | Results Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting genprex.com ↗
TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC) |
| 2025-11-24 | Genprex, Inc. | Results Data from Genprex’s Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer genprex.com ↗
The Phase 1 dose escalation portion of the trial was designed primarily to assess safety, however, the Company believes promising efficacy results were also observed. |
| 2025-10-28 | Genprex, Inc. | Results Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics genprex.com ↗
These data also add to the existing preclinical data showing that REQORSA has significant activity on its own as well as when combined with other therapies in a mouse xenograft model with ALK-EML4 rearrangement. |
| 2025-10-23 | Genprex, Inc. | Results Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics genprex.com ↗
Our researchers found that REQORSA alone or in combination with alectinib was able to shrink tumors by 79 percent |
| 2025-04-30 | Genprex, Inc. | Results Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting genprex.com ↗
Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer |
| 2025-04-22 | Genprex, Inc. | Results Genprex Announces Research Collaborators’ Abstract Published in Cancer Research Supplement Proceedings genprex.com ↗ |
| 2024-12-16 | Genprex, Inc. | Results Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer genprex.com ↗
Based on full safety data, which showed no dose limiting toxicities (DLTs), the SRC determined that the Recommended Phase 2 Dose (RP2D) of REQORSA will be 0.12 mg/kg. |
| 2024-10-28 | Genprex, Inc. | Results Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma genprex.com ↗
The collaborators presented posters on positive preclinical data from studies of Genprex’s lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma. |
| 2024-10-15 | Genprex, Inc. | Results Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer genprex.com ↗
There were no dose limiting toxicities (DLTs) in this dose group and the SRC recommended moving up to the highest dose group planned in the trial. |
| 2024-10-10 | Genprex, Inc. | Results Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics genprex.com ↗
“The compelling data made available today validates the potential of REQORSA as a therapeutic treatment for some of the most difficult to treat cancers and diseases, including Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma,” said Ryan Confer, President and Chief Executive Officer at Genprex. |
| 2024-08-14 | Genprex, Inc. | Results Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer genprex.com ↗
Two patients in the Acclaim-1 study have had prolonged Progression Free Survival (PFS) and importantly, the first treated patient in the Acclaim-3 study attained a Partial Remission (PR) from the start of maintenance therapy. |
| 2024-04-09 | Genprex, Inc. | Results Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting genprex.com ↗ |
| 2024-03-06 | Genprex, Inc. | Results Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting genprex.com ↗
The study further suggested that REQORSA may play an important role as a cancer treatment to target and disrupt the metabolism of cancer cells, leading to a decrease in the rate of glycolysis. |
| 2023-10-04 | Genprex, Inc. | Results Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics genprex.com ↗
Of the 12 patients treated with escalating doses of REQORSA and standard doses of Tagrisso, all of whom had progressed on Tagrisso containing regimens, two patients experienced prolonged time to progression, including one with continuing partial response. |
| 2023-08-10 | Genprex, Inc. | Regulatory Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer genprex.com ↗ |
| 2023-05-25 | Genprex, Inc. | Results Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting genprex.com ↗
Results Show Combination of REQORSA® and Tagrisso® was Well Tolerated at All Three Dose Levels of Phase 1 Trial with Encouraging Evidence of Efficacy Observed |
| 2020-10-29 | Genprex, Inc. | Regulatory Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer genprex.com ↗ |
| 2020-06-25 | Genprex, Inc. | Regulatory Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate genprex.com ↗
“The USAN’s adoption of our non-proprietary name is another step toward advancing our lead drug candidate, GPX-001 for non-small cell lung cancer, toward commercialization,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. |
All press releases naming this drug 40 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | quaratusugene ozeplasmid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05703971 ↗ |
| Known as | Oncoprex | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594390 ↗ |
| Action | Restore | “reestablishing pathways that promote cancer cell death” NCT04486833 ↗ |
| Modality | Other / unclassified | “experimental nonviral immunogene therapy” NCT05703971 ↗ |
| Route | Intravenous | “intravenous administration once every 21 days” NCT04486833 ↗ |
| Target | TUSC2 | “utilizing the TUSC2 gene” NCT05703971 ↗ |